Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Aug;202(4):367-383.
doi: 10.1007/s00408-024-00717-y. Epub 2024 Jun 19.

Efficacy of Biologics in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis

Xiaoying Chen #  1 , Haopeng Zhi #  1 , Xiaohu Wang #  2 , Zicong Zhou  1 , Huiting Luo  1 , Jing Li  1 , Roma Sehmi  3 , Paul M O'Byrne  3 , Ruchong Chen  4   5
Affiliations
Meta-Analysis

Efficacy of Biologics in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis

Xiaoying Chen et al. Lung. 2024 Aug.

Abstract

Background: Treatment of allergic bronchopulmonary aspergillosis (ABPA) is challenging. Biological therapies have been reported as adjunctive treatments for ABPA, primarily in case series or case reports. This study aimed to analyze the efficacy of biologics for managing ABPA both qualitatively and quantitatively.

Methods: All articles on APBA published in October 2023 were searched in PubMed, Web of Science, ClinicalTrials.gov, and Embase databases. The effects of interest were the mean changes from baseline for outcomes, including exacerbation rates, oral corticosteroids usage (OCS), and total immunoglobulin E (IgE) levels. Reported outcomes were quantitatively synthesized by usual or individual patient data (IPD) meta-analyses. PROSPERO registration number: CRD42022373396.

Results: A total of 86 studies were included in the systematic review including 346 patients. Sixteen studies on omalizumab were pooled for the usual meta-analysis. Omalizumab therapy significantly reduced exacerbation rates (- 2.29 [95%CI - 3.32, - 1.26]), OCS dosage (- 10.91 mg [95%CI - 18.98, - 2.85]), and total IgE levels (- 273.07 IU/mL [95%CI - 379.30, - 166.84]), meanwhile improving FEV1% predicted (10.09% [95%CI 6.62, 13.55]). Thirty-one studies on dupilumab, mepolizumab, or benralizumab were pooled to perform an IPD meta-analysis, retrospectively. Both dupilumab and mepolizumab significantly reduced exacerbation rates, OCS, and total IgE levels. Benralizumab showed a similar trend, but it was not statistically significant. Tezepelumab showed weak evidence of its effects on ABPA. All five biologics led to milder clinical symptoms (e.g., cough, wheezing) with serious adverse effects that happened once in omalizumab treatment.

Conclusion: These results indicate the clinical benefit of omalizumab, dupilumab, and mepolizumab in patients with ABPA. Further randomized, controlled studies with a larger sample size and longer follow-up are needed to confirm these findings.

Keywords: ABPA; Allergic Bronchopulmonary Aspergillosis; Biological agents; Efficacy; meta-analysis.

PubMed Disclaimer

References

    1. Denning DW, Pleuvry A, Cole DC (2013) Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol 51:361–370. https://doi.org/10.3109/13693786.2012.738312 - DOI - PubMed
    1. Maturu VN, Agarwal R (2015) Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis. Clin Exp Allergy J Br Soc Allergy Clin Immunol 45:1765–1778. https://doi.org/10.1111/cea.12595 - DOI
    1. Stevens DA, Moss RB, Kurup VP et al (2003) Allergic bronchopulmonary aspergillosis in cystic fibrosis–state of the art: cystic fibrosis foundation consensus conference. Clin Infect Dis Off Publ Infect Dis Soc Am 37(Suppl 3):S225-264. https://doi.org/10.1086/376525 - DOI
    1. Riscili BP, Wood KL (2009) Noninvasive pulmonary Aspergillus infections. Clin Chest Med 30(315–335):vii. https://doi.org/10.1016/j.ccm.2009.02.008 - DOI - PubMed
    1. Agarwal R, Sehgal IS, Dhooria S et al (2020) Allergic bronchopulmonary aspergillosis. Indian J Med Res 151:529–549. https://doi.org/10.4103/ijmr.IJMR_1187_19 - DOI - PubMed - PMC

Publication types

MeSH terms

LinkOut - more resources